|
Regions of significance and voting for a positive treatment effect in three uncontrolled studies on Bosentan in PAH based on the approach presented in this paper |
||||||
| Study |
N |
6MWD at Baseline |
6MWD at week 16 |
correlation |
region of significance |
Vote of significance |
|
|
||||||
| Souza et al. 2005 [18] |
15 |
396 ± 135 |
434 ± 137 |
r = 0.2 |
[0;337] & [672;∞] |
Unlikely |
| r = 0.5 |
[0;300] |
Unlikely |
||||
| r = 0.8 |
- |
Never |
||||
|
|
||||||
| Provencher et al. 2006 [19] |
99 |
322 ± 105 |
364 ± 109 |
r = 0.2 |
[0;347] & [410;∞] |
Probably |
| r = 0.5 |
[0;367] & [481;∞] |
Probably |
||||
| r = 0.8 |
[0;448] & [1292;∞] |
Most likely |
||||
|
|
||||||
| Apostolopoulou et al. 2006 [20] |
21 |
416 ± 105 |
459 ± 101 |
r = 0.2 |
[0;412] & [575;∞] |
Unlikely |
| r = 0.5 |
[0;420] & [820;∞] |
Unlikely |
||||
| r = 0.8 |
[0;466] |
Probably |
||||
|
(N- number of patients, 6MWT-6-minute walk distance, data before and after intervention is mean ± standard deviation, region of significance: only 6MWD values > 0 reported) | ||||||
Ostermann et al. BMC Medical Research Methodology 2008 8:52 doi:10.1186/1471-2288-8-52 |
||||||